가축 백신 시장 규모, 점유율, 성장률 및 시장 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of livestock vaccines Market

The global livestock vaccines market was valued at USD 6.33 billion in 2025 and is projected to grow to USD 6.68 billion in 2026, reaching USD 11.39 billion by 2034, registering a CAGR of 6.9% during the forecast period. North America dominated the market in 2025 with a 46.90% share, driven by a large livestock population, government-backed vaccination programs, and the widespread adoption of advanced vaccines. The U.S. livestock vaccines market is expected to reach USD 4.29 billion by 2032, supported by ongoing R&D initiatives and government efforts to promote animal health.

Market Overview

Livestock vaccines play a crucial role in protecting farm animals from infectious diseases such as foot-and-mouth disease, infectious bovine rhinotracheitis (IBR), Newcastle disease, and porcine reproductive and respiratory syndrome (PRRS). Vaccines are administered through various routes, including parenteral, oral, intranasal, and subcutaneous, and are available in multiple forms such as live attenuated, inactivated, recombinant, and toxoid vaccines. These vaccines help reduce economic losses associated with livestock illnesses and support global food security.

Market Drivers

The market growth is fueled by the rising prevalence of zoonotic diseases, which can transmit from animals to humans, prompting governments and livestock owners to adopt preventive vaccination programs. In the U.S., around 5,000 animal rabies cases are reported annually, with over 90% occurring in wildlife, highlighting the critical need for livestock vaccines. Increasing awareness among farmers about animal healthcare and the benefits of immunization is further contributing to market growth.

R&D initiatives by major players also drive market expansion. Companies are investing in the development of advanced vaccines, such as protein subunit vaccines and recombinant vaccines, to address emerging diseases and enhance immune responses in livestock. For instance, Boehringer Ingelheim introduced VAXXITEK HVT+IBD+ILT, a recombinant vaccine for poultry protection against Marek's disease, infectious bursal disease, and infectious laryngotracheitis.

Market Restraints

Despite growth opportunities, the market faces challenges from adverse effects associated with vaccines. Live-attenuated vaccines may sometimes cause mild reactions, while certain vaccines show limited efficacy against targeted diseases. Such concerns can reduce the adoption rate among livestock owners and temper market growth in some regions.

Market Segmentation

By Type:

• Live attenuated vaccines dominated the market in 2026 with a 38.93% share, due to strong and long-lasting immune responses.
• Recombinant vaccines are expected to witness the highest CAGR from 2026 to 2034, driven by innovation and increasing adoption for poultry and swine protection.
• Inactivated vaccines and others also contribute to market growth.

By Animal Type:

• Bovine vaccines accounted for the largest share in 2026 at 58%, supported by the increasing global cattle population.
• Poultry vaccines are projected to grow at the highest CAGR over 2025-2032 due to rising disease prevalence.
• Swine/porcine vaccines remain significant due to outbreaks of PRRS and swine influenza.

By Route of Administration:

• Parenteral vaccines held the largest share in 2026 at 67.16%, providing reliable immune responses and rapid onset.
• Oral vaccines are growing due to innovation and increasing clinical trials.
• Other routes, such as intranasal, are limited to specific use cases.

By Distribution Channel:

• Veterinary clinics dominated in 2024 and continue to lead due to growing livestock visits and availability of veterinarians.
• Veterinary hospitals are expanding, particularly for post-vaccination care.

Regional Insights

North America: Market size of USD 2.97 billion in 2025, projected USD 3.13 billion in 2026, driven by vaccine launches, adoption of advanced products, and large livestock populations. U.S. market projected to reach USD 2.9 billion in 2026.

Europe: Steady growth driven by poultry and swine adoption, zoonotic disease prevalence, and government awareness campaigns. UK and Germany markets projected at USD 0.24 billion and USD 0.33 billion in 2026, respectively.

Asia Pacific: Highest CAGR expected, led by vaccination programs and awareness initiatives in China, India, and Japan. Markets projected at Japan USD 0.25 billion, China USD 0.28 billion, and India USD 0.10 billion in 2026.

Latin America & Middle East & Africa: Growing market share due to increasing livestock diseases, technological vaccine launches, and enhanced animal healthcare infrastructure.

Key Market Players

Leading companies include Zoetis Services LLC, Merck Animal Health, Boehringer Ingelheim International GmbH, Virbac, Ceva, Elanco, and HIPRA, focusing on R&D, new product launches, mergers, and market expansion to strengthen their global presence. Strategic initiatives such as partnerships, acquisitions, and novel vaccine development are key for market leadership.

Conclusion

The livestock vaccines market is projected to grow from USD 6.33 billion in 2025 to USD 11.39 billion by 2034, driven by rising zoonotic disease prevalence, government initiatives, R&D investment, and technological advancements in vaccine development. Adoption across bovine, poultry, and swine populations, along with increasing awareness and improved vaccination programs, positions the market for sustained growth globally.

Segmentation

By Type

• Inactivated
• Live Attenuated
• Recombinant
• Others

By Animal Type

• Bovine
• Swine/ Porcine
• Poultry
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Others

By Geography

• North America (By Type, Animal Type, By Route of Administration, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Type, Animal Type, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Animal Type, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Animal Type, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of the Latin America
• Middle East & Africa (By Type, Animal Type, By Route of Administration, By Distribution Channel, and By Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Veterinary Vaccination Rates: Key Conditions
• 4.2. Overview on Vaccination Programs
• 4.3. Key Industry Developments, Mergers, Acquisitions, Partnerships, etc.
• 4.4. Impact of COVID-19 Pandemic on Livestock Vaccines Market

5. Global Livestock Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Inactivated
  • 5.1.2. Live Attenuated
  • 5.1.3. Recombinant
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Animal Type
  • 5.2.1. Bovine
  • 5.2.2. Swine/ Porcine
  • 5.2.3. Poultry
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Veterinary Hospitals
  • 5.4.2. Veterinary Clinics
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Livestock Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Inactivated
  • 6.1.2. Live Attenuated
  • 6.1.3. Recombinant
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Animal Type
  • 6.2.1. Bovine
  • 6.2.2. Swine/ Porcine
  • 6.2.3. Poultry
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Veterinary Hospitals
  • 6.4.2. Veterinary Clinics
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Livestock Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Inactivated
  • 7.1.2. Live Attenuated
  • 7.1.3. Recombinant
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Animal Type
  • 7.2.1. Bovine
  • 7.2.2. Swine/ Porcine
  • 7.2.3. Poultry
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Veterinary Hospitals
  • 7.4.2. Veterinary Clinics
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. United Kingdom
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Livestock Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Inactivated
  • 8.1.2. Live Attenuated
  • 8.1.3. Recombinant
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Animal Type
  • 8.2.1. Bovine
  • 8.2.2. Swine/ Porcine
  • 8.2.3. Poultry
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Veterinary Hospitals
  • 8.4.2. Veterinary Clinics
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. China
  • 8.5.2. India
  • 8.5.3. Japan
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Livestock Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Inactivated
  • 9.1.2. Live Attenuated
  • 9.1.3. Recombinant
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Animal Type
  • 9.2.1. Bovine
  • 9.2.2. Swine/ Porcine
  • 9.2.3. Poultry
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Veterinary Hospitals
  • 9.4.2. Veterinary Clinics
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Livestock Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Inactivated
  • 10.1.2. Live Attenuated
  • 10.1.3. Recombinant
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Animal Type
  • 10.2.1. Bovine
  • 10.2.2. Swine/ Porcine
  • 10.2.3. Poultry
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Veterinary Hospitals
  • 10.4.2. Veterinary Clinics
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. South Africa
  • 10.5.2. GCC
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Boehringer Ingelheim International GmbH
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Virbac
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck Animal Health (Merck & Co., Inc.)
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Zoetis Services LLC
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Ceva
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Elanco
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Nisseiken Co., Ltd.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Neogen Corporation
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)